Aldosterone activates transcription factor Nrf2 in kidney cells both in vitro and in vivo

Antioxidants and Redox Signaling

Volumn 21, Issue 15, 2014, Pages 2126-2142

  Queisser, Nina ^a,c   Oteiza, Patricia I ^b   Link, Samuel ^a   Hey, Valentin ^a   Stopper, Helga ^a   Schupp, Nicole ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

8 HYDROXYGUANINE; ALDOSTERONE; CALCIUM; GLUTATHIONE; MINERALOCORTICOID RECEPTOR; NITRIC OXIDE SYNTHASE; NITROGEN DERIVATIVE; PROTEIN KINASE C; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SULFORAPHANE; TRANSCRIPTION FACTOR NRF2; ISOTHIOCYANIC ACID DERIVATIVE; NFE2L2 PROTEIN, RAT; REACTIVE NITROGEN SPECIES; SULFORAFAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DETOXIFICATION; DNA DAMAGE; DOUBLE STRANDED DNA BREAK; GLUTATHIONE METABOLISM; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CELL; KIDNEY FUNCTION; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; ANIMAL; BIOSYNTHESIS; CYTOLOGY; GENE EXPRESSION; KIDNEY PROXIMAL TUBULE; LLC PK1 CELL LINE; METABOLISM; PHYSIOLOGY; PIG; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT; TRANSCRIPTION INITIATION;

ALDOSTERONE; ANIMALS; DNA DAMAGE; GENE EXPRESSION; GLUTATHIONE; ISOTHIOCYANATES; KIDNEY TUBULES, PROXIMAL; LLC-PK1 CELLS; MALE; NADPH OXIDASE; NF-E2-RELATED FACTOR 2; NITRIC OXIDE SYNTHASE; OXIDATIVE STRESS; RATS, SPRAGUE-DAWLEY; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN SPECIES; RECEPTORS, MINERALOCORTICOID; SIGNAL TRANSDUCTION; SWINE; TRANSCRIPTIONAL ACTIVATION;

EID: 84908351480     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2013.5565     Document Type: Article

References (60)

1. Aoki Y, Sato H, Nishimura N, Takahashi S, Itoh K, and Yamamoto M. Accelerated DNA adduct formation in the lung of the Nrf2 knockout mouse exposed to diesel exhaust. Toxicol Appl Pharmacol 173: 154-160, 2001.
2. Bonner WM, Redon CE, Dickey JS, Nakamura AJ, Sedelnikova OA, Solier S, and Pommier Y. GammaH2AX and cancer. Nat Rev Cancer 8: 957-967, 2008.
3. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
4. Burdette D, Olivarez M, and Waris G. Activation of transcription factor Nrf2 by hepatitis C virus induces the cellsurvival pathway. J Gen Virol 91: 681-690, 2010.
5. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica D, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 117: e510-e526, 2008.
6. Chen TM, Li J, Liu L, Fan L, Li XY, Wang YT, Abraham NG, and Cao J. Effects of heme oxygenase-1 upregulation on blood pressure and cardiac function in an animal model of hypertensive myocardial infarction. Int J Mol Sci 14: 2684-2706, 2013.
7. Cheng KC, Cahill DS, Kasai H, Nishimura S, and Loeb LA. 8-Hydroxyguanine, an abundant form of oxidative DNA damage, causes G-T and A-C substitutions. J Biol Chem 267: 166-172, 1992.
8. Cooke MS, Olinski R, and Evans MD. Does measurement of oxidative damage to DNA have clinical significance? Clin Chim Acta 365: 30-49, 2006.
9. Crow JP. Dichlorodihydrofluorescein and dihydrorhodamine 123 are sensitive indicators of peroxynitrite in vitro: implications for intracellular measurement of reactive nitrogen and oxygen species. Nitric Oxide 1: 145-157, 1997.
10. de Zeeuw D, Akizawa T, Agarwal R, Audhya P, Bakris GL, Chin M, Krauth M, Lambers Heerspink HJ, Meyer CJ, McMurray JJ, et al. Rationale and trial design of bardoxolone methyl evaluation in patients with chronic kidney disease and type 2 diabetes: the occurrence of renal events (BEACON). Am J Nephrol 37: 212-222, 2013.
11. Dhakshinamoorthy S and Porter AG. Nitric oxide-induced transcriptional up-regulation of protective genes by Nrf2 via the antioxidant response element counteracts apoptosis of neuroblastoma cells. J Biol Chem 279: 20096-20107, 2004.
12. Friis S, Sorensen HT, Mellemkjaer L, McLaughlin JK, Nielsen GL, Blot WJ, and Olsen JH. Angiotensin-converting enzyme inhibitors and the risk of cancer: a population-based cohort study in Denmark. Cancer 92: 2462-2470, 2001.
13. Funder J and New MI. Low renin hypertension (LRH): shades of John Laragh. Trends Endocrinol Metab 19: 83, 2008.
14. Gao L and Mann GE. Vascular NAD(P)H oxidase activation in diabetes: a double-edged sword in redox signalling. Cardiovasc Res 82: 9-20, 2009.
15. Gegg ME, Beltran B, Salas-Pino S, Bolanos JP, Clark JB, Moncada S, and Heales SJ. Differential effect of nitric oxide on glutathione metabolism and mitochondrial function in astrocytes and neurones: implications for neuroprotection/neurodegeneration? J Neurochem 86: 228-237, 2003.
16. Gekle M, Freudinger R, Mildenberger S, and Silbernagl S. Aldosterone interaction with epidermal growth factor receptor signaling in MDCK cells. Am J Physiol Renal Physiol 282: F669-F679, 2002.
17. Gius D and Spitz DR. Redox signaling in cancer biology. Antioxid Redox Signal 8: 1249-1252, 2006.
18. Gomez-Guzman M, Jimenez R, Sanchez M, Zarzuelo MJ, Galindo P, Quintela AM, Lopez-Sepulveda R, Romero M, Tamargo J, Vargas F, et al. Epicatechin lowers blood pressure, restores endothelial function, and decreases oxidative stress and endothelin-1 and NADPH oxidase activity in DOCA-salt hypertension. Free Radic Biol Med 52: 70-79, 2012.
19. Griendling KK, Sorescu D, and Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res 86: 494-501, 2000.
20. Grossman E, Messerli FH, Boyko V, and Goldbourt U. Is there an association between hypertension and cancer mortality? Am J Med 112: 479-486, 2002.
21. Habib SL, Danial E, Nath S, Schneider J, Jenkinson CP, Duggirala R, Abboud HE, and Thameem F. Genetic polymorphisms in OGG1 and their association with angiomyolipoma, a benign kidney tumor in patients with tuberous sclerosis. Cancer Biol Ther 7: 23-27, 2008.
22. Harvey BJ and Higgins M. Nongenomic effects of aldosterone on Ca2 + in M-1 cortical collecting duct cells. Kidney Int 57: 1395-1403, 2000.
23. Hayashi H, Kobara M, Abe M, Tanaka N, Gouda E, Toba H, Yamada H, Tatsumi T, Nakata T, and Matsubara H. Aldosterone nongenomically produces NADPH oxidasedependent reactive oxygen species and induces myocyte apoptosis. Hypertens Res 31: 363-375, 2008.
24. Huang HC, Nguyen T, and Pickett CB. Regulation of the antioxidant response element by protein kinase C-mediated phosphorylation of NF-E2-related factor 2. Proc Natl Acad Sci USA 97: 12475-12480, 2000.
25. Jackson SP and Bartek J. The DNA-damage response in human biology and disease. Nature 461: 1071-1078, 2009.
26. Jeggo PA and Lobrich M. DNA double-strand breaks: their cellular and clinical impact? Oncogene 26: 7717-7719, 2007.
27. Kang KW, Choi SH, and Kim SG. Peroxynitrite activates NF-E2-related factor 2/antioxidant response element through the pathway of phosphatidylinositol 3-kinase: the role of nitric oxide synthase in rat glutathione S-transferase A2 induction. Nitric Oxide 7: 244-253, 2002.
28. Kim HJ and Vaziri ND. Contribution of impaired Nrf2-Keap1 pathway to oxidative stress and inflammation in chronic renal failure. Am J Physiol Renal Physiol 298: F662-F671, 2010.
29. Kruger NJ. The Bradford method for protein quantitation. Methods Mol Biol 32: 9-15, 1994.
30. Lamprecht MR, Sabatini DM, and Carpenter AE. Cell-Profiler: free, versatile software for automated biological image analysis. Biotechniques 42: 71-75, 2007.
31. Lans H and Hoeijmakers JH. Genome stability, progressive kidney failure and aging. Nat Genet 44: 836-838, 2012.
32. Lau A, Villeneuve NF, Sun Z, Wong PK, and Zhang DD. Dual roles of Nrf2 in cancer. Pharmacol Res 58: 262-270, 2008.
33. Leckie C, Chapman KE, Edwards CR, and Seckl JR. LLCPK1 cells model 11 beta-hydroxysteroid dehydrogenase type 2 regulation of glucocorticoid access to renal mineralocorticoid receptors. Endocrinology 136: 5561-5569, 1995.
34. Losel RM, Feuring M, Falkenstein E, and Wehling M. Nongenomic effects of aldosterone: cellular aspects and clinical implications. Steroids 67: 493-498, 2002.
35. Mackenzie GG, Zago MP, Keen CL, and Oteiza PI. Low intracellular zinc impairs the translocation of activated NFkappa B to the nuclei in human neuroblastoma IMR-32 cells. J Biol Chem 277: 34610-34617, 2002.
36. McKinnon PJ and Caldecott KW. DNA strand break repair and human genetic disease. Annu Rev Genomics Hum Genet 8: 37-55, 2007.
37. Naganuma T, Nakayama T, Sato N, Fu Z, Soma M, Yamaguchi M, Shimodaira M, Aoi N, and Usami R. Haplotypebased case-control study on human apurinic/apyrimidinic endonuclease 1/redox effector factor-1 gene and essential hypertension. Am J Hypertens 23: 186-191, 2010.
38. Osburn WO and Kensler TW. Nrf2 signaling: an adaptive response pathway for protection against environmental toxic insults. Mutat Res 659: 31-39, 2008.
39. Paravicini TM and Touyz RM. NADPH oxidases, reactive oxygen species, and hypertension: clinical implications and therapeutic possibilities. Diabetes Care 31 Suppl 2: S170-S180, 2008.
40. Pergola PE, Raskin P, Toto RD, Meyer CJ, Huff JW, Grossman EB, Krauth M, Ruiz S, Audhya P, Christ-Schmidt H, et al. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med 365: 327-336, 2011.
41. Queisser N, Amann K, Hey V, Habib SL, and Schupp N. Blood pressure has only minor influence on aldosteroneinduced oxidative stress and DNA damage in vivo. Free Radic Biol Med 54: 17-25, 2013.
42. Queisser N, Fazeli G, and Schupp N. Superoxide anion and hydrogen peroxide-induced signaling and damage in angiotensin II and aldosterone action. Biol Chem 391: 1265-1279, 2010.
43. Queisser N, Oteiza PI, Stopper H, Oli RG, and Schupp N. Aldosterone induces oxidative stress, oxidative DNA damage and NF-kappaB-activation in kidney tubule cells. Mol Carcinog 50: 123-135, 2011.
44. Queisser N, Schupp N, Stopper H, Schinzel R, and Oteiza PI. Aldosterone increases kidney tubule cell oxidants through calcium-mediated activation of NADPH oxidase and nitric oxide synthase. Free Radic Biol Med 51: 1996-2006, 2011.
45. Rasband WS. Image J Software Program. U.S. National Institute of Health, Bethesda, MD, 1997-2008.
46. Rogerson FM, Yao YZ, Elsass RE, Dimopoulos N, Smith BJ, and Fuller PJ. A critical region in the mineralocorticoid receptor for aldosterone binding and activation by cortisol: evidence for a common mechanism governing ligand binding specificity in steroid hormone receptors. Mol Endocrinol 21: 817-828, 2007.
47. Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, Ganzaroli C, Giacchetti G, Letizia C, Maccario M, et al. A prospective study of the prevalence of primary aldosteronism in 1, 125 hypertensive patients. J Am Coll Cardiol 48: 2293-2300, 2006.
48. Schupp N, Kolkhof P, Queisser N, Gartner S, Schmid U, Kretschmer A, Hartmann E, Oli RG, Schafer S, and Stopper H. Mineralocorticoid receptor-mediated DNA damage in kidneys of DOCA-salt hypertensive rats. FASEB J 25: 968-978, 2011.
49. Schupp N, Queisser N, Wolf M, Kolkhof P, Barfacker L, Schafer S, Heidland A, and Stopper H. Aldosterone causes DNA strand breaks and chromosomal damage in renal cells, which are prevented by mineralocorticoid receptor antagonists. Horm Metab Res 42: 458-465, 2010.
50. Schupp N, Schmid U, Rutkowski P, Lakner U, Kanase N, Heidland A, and Stopper H. Angiotensin II-induced genomic damage in renal cells can be prevented by angiotensin II type 1 receptor blockage or radical scavenging. Am J Physiol Renal Physiol 292: F1427-F1434, 2007.
51. Shih AY, Johnson DA, Wong G, Kraft AD, Jiang L, Erb H, Johnson JA, and Murphy TH. Coordinate regulation of glutathione biosynthesis and release by Nrf2-expressing glia potently protects neurons from oxidative stress. J Neurosci 23: 3394-3406, 2003.
52. Skott O, Uhrenholt TR, Schjerning J, Hansen PB, Rasmussen LE, and Jensen BL. Rapid actions of aldosterone in vascular health and disease-friend or foe? Pharmacol Ther 111: 495-507, 2006.
53. Stenvinkel P and Larsson TE. Chronic kidney disease: a clinical model of premature aging. Am J Kidney Dis 62: 339-351, 2013.
54. Surh YJ, Kundu JK, Li MH, Na HK, and Cha YN. Role of Nrf2-mediated heme oxygenase-1 upregulation in adaptive survival response to nitrosative stress. Arch Pharm Res 32: 1163-1176, 2009.
55. Surh YJ, Kundu JK, and Na HK. Nrf2 as a master redox switch in turning on the cellular signaling involved in the induction of cytoprotective genes by some chemopreventive phytochemicals. Planta Med 74: 1526-1539, 2008.
56. Surh YJ and Na HK. NF-kappaB and Nrf2 as prime molecular targets for chemoprevention and cytoprotection with anti-inflammatory and antioxidant phytochemicals. Genes Nutr 2: 313-317, 2008.
57. Talalay P, Fahey JW, Holtzclaw WD, Prestera T, and Zhang Y. Chemoprotection against cancer by phase 2 enzyme induction. Toxicol Lett 82: 173-179, 1995.
58. Weber KT. Aldosterone in congestive heart failure. N Engl J Med 345: 1689-1697, 2001.
59. Westhoff JH, Hilgers KF, Steinbach MP, Hartner A, Klanke B, Amann K, and Melk A. Hypertension induces somatic cellular senescence in rats and humans by induction of cell cycle inhibitor p16INK4a. Hypertension 52: 123-129, 2008.
60. Yisireyili M, Shimizu H, Saito S, Enomoto A, Nishijima F, and Niwa T. Indoxyl sulfate promotes cardiac fibrosis with enhanced oxidative stress in hypertensive rats. Life Sci 92: 1180-1185, 2013.